MicroAlgo’s Cost-Driven Earnings Spark Cigar Butt vs. Compounder Debate as P/E Plummets to 0.78

The numbers tell a story of dramatic transformation. For the full year 2025, MicroAlgo reported a net profit of RMB 127.56 million, a figure that management describes as "outstanding." More striking is the expansion of its equity base, which more than doubled to RMB 2,321.80 million. On the surface, this looks like a classic value story: a company building substantial intrinsic value on its balance sheet while generating real profits. Yet, the path to that profit raises a fundamental question about sustainability.

The key tension emerges when we look at the half-year trend. For the six months ended June 30, 2025, revenue declined year-over-year to CNY 188.11 million, down from CNY 290.44 million in the same period the prior year. Yet, net income rose to CNY 26.47 million from CNY 16.26 million. This disconnect-profit growth while sales shrink-is a classic signal of cost control or operational efficiency gains. For a value investor, this is a double-edged sword. It demonstrates management's ability to improve the bottom line from a given revenue base, which is a positive. But it also suggests the company's growth engine may be sputtering, raising questions about whether this profit expansion can be maintained or compounded over the long term.

The market's verdict on this quality of earnings is stark. As of January 2026, MicroAlgo's trailing P/E ratio stood at 0.78. This is a dramatic decline from its 12-month average of 13.58. A P/E below 1 indicates the market is pricing the company as if its earnings are worth less than its book value, a level of skepticism that often reflects deep concerns about future prospects. While such a low multiple can signal a potential bargain, it also represents a market that has severely discounted the company's story. The plunge from a 12-month average P/E of over 13 to under 1 underscores how quickly sentiment can turn when growth stalls and profitability appears to be a function of cuts rather than compounding.

The bottom line is that the 2025 results present a puzzle. The profit and equity figures are real and impressive on paper. But the source of that profit-cost discipline amid declining revenue-creates a vulnerability. For a true compounder, earnings growth should be driven by expanding sales and widening moats. For a cigar butt, it's about finding a cheap asset. MicroAlgo's 2025 performance, with its sharp P/E collapse, suggests the market is leaning toward the latter view, questioning whether the current profit level is a sustainable foundation or a temporary peak.

The Competitive Moat and Long-Term Compounding

For a value investor, the ultimate question is whether a business can compound value over decades. MicroAlgo's operating sector-central processing algorithm services-is inherently scalable, but scalability alone does not build a durable moat. Management's attribution of 2025's profit growth to cost control and operational efficiency is a necessary step for a turnaround, but it is not sufficient for a wide moat. True economic advantage comes from being the only or best provider in a niche, or from network effects and switching costs that make competition difficult. The evidence shows no indication that MicroAlgo has achieved this. Its services, while valuable, appear to be a commodity-like layer of optimization that clients could potentially source elsewhere. Without a clear, defensible advantage, the company's earnings power remains vulnerable to price competition and client renegotiation.

The market's skepticism is reflected in its micro-cap status and volatile price action. With a market capitalization of $100.62 million, MicroAlgo operates in a category where liquidity is thin and sentiment swings can be extreme. The stock's recent history is telling. Following its last earnings release on April 28, 2025, shares declined 10.2% the next day. This sharp sell-off is a classic reaction to a company that has been priced for perfection but delivers a story of cost-cutting profits on shrinking revenue. It signals that investors saw no new catalyst for growth or moat-building, only a confirmation of the existing operational discipline. For a compounder, such a reaction would be a temporary blip; for a business viewed as a potential cigar butt, it is the market pricing in the risk that the current profit level is the peak.

The bottom line is that MicroAlgo's 2025 results, while impressive on paper, do not yet demonstrate the characteristics of a durable compounder. The company has successfully managed its costs and expanded its equity, but it has not shown the ability to grow its revenue base or widen its competitive advantage. Its micro-cap size and the market's violent reaction to its earnings underscore the uncertainty around its long-term trajectory. For value investors, this creates a tension: the low P/E ratio suggests deep value, but the lack of a visible moat questions whether that value is sustainable or merely a function of a temporary cost-cutting cycle. The path to becoming a true compounder requires more than operational efficiency; it demands a clear, repeatable advantage that can protect earnings through economic cycles. MicroAlgo has not yet proven it possesses that.

Valuation, Margin of Safety, and the Path Forward

The numbers present a stark contrast between apparent cheapness and deep-seated doubt. As of January 2026, MicroAlgo trades at a trailing P/E ratio of 0.78. This is the kind of multiple that a value investor might salivate over, suggesting the market is pricing the company for a value destruction scenario rather than a business worth owning. The plunge from a 12-month average of 13.58 underscores how completely sentiment has collapsed. On paper, this offers a potential margin of safety: you are paying less than the book value for the earnings stream. Yet, this margin is built on a foundation of profound skepticism about the future.

The primary risk is that this profit growth is not sustainable. The 2025 results, with net income rising while revenue declined, point squarely to cost control and operational efficiency as the driver. For a cigar butt, that's the story. You buy a company with a cheap asset, and the profit from cost cuts is the "butt" you smoke. But for a compounder, that's a red flag. It suggests the current earnings power is a function of cuts, not of expanding sales or a widening moat. If those cost savings are one-time or non-recurring, the profit could vanish just as quickly as it appeared, leaving the stock with no earnings to support its price. The market's violent reaction to the last earnings release-a 10.2% decline the next day-tells you exactly what investors fear: a confirmation that the growth story is over.

So, what would confirm the investment thesis? For a value investor, the catalyst is clear: evidence that the 2025 profit growth is supported by recurring earnings and that the company can stabilize or grow revenue while maintaining its improved margins. This would shift the narrative from a cost-cutting turnaround to a sustainable, profitable business. The path forward requires management to demonstrate that the operational discipline is now embedded and that the company can begin to scale its top line again. Until then, the low P/E ratio is less a bargain and more a warning label. It reflects a market that has already priced in the worst-case scenario of a temporary profit peak. The margin of safety exists, but it is a narrow one, contingent entirely on the company proving it can move beyond the cigar butt and start building a true compounder.